Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ONTX

Onconova Therapeutics (ONTX) Stock Price, News & Analysis

Onconova Therapeutics logo

About Onconova Therapeutics Stock (NASDAQ:ONTX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.67
$1.01
52-Week Range
N/A
Volume
1.28 million shs
Average Volume
96,681 shs
Market Capitalization
$20.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Stock News Headlines

TRAW Traws Pharma, Inc.
Onconova and Trawsfynydd merge to form Traws Pharma
Texas approves new currency
Rural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the global banking system... backed up by Elon Musk and the White House.
Onconova Acquires Trawsfynydd To Form Traws Pharma
See More Headlines

ONTX Stock Analysis - Frequently Asked Questions

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its quarterly earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%.

Onconova Therapeutics shares reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Onconova Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Ocugen (OCGN), Bionano Genomics (BNGO), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
11/11/2021
Today
2/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONTX
Employees
16
Year Founded
N/A

Profitability

Net Income
$-18,960,000.00
Net Margins
-8,930.97%
Pretax Margin
-8,930.97%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$1.35 per share

Miscellaneous

Free Float
20,310,000
Market Cap
$20.90 million
Optionable
Optionable
Beta
1.38

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ONTX) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners